Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 10/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | BRAF | P15056 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.72 |
| ▸ | RAF1 | P04049 | 2/20 | 0.72 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.72 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.72 |
| ▸ | NEK2 | P51955 | 2/20 | 0.72 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.72 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.72 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.72 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.72 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.72 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.72 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30866642 | 1.00 | CYP2C9 (0.78) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL21624488 | 0.94 | CYP2C9 (0.76) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL21624482 | 0.94 | CYP2C9 (0.76) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL30866619 | 0.94 | CYP2C9 (0.76) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL20408837 | 0.93 | CYP2C9 (0.75) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL29796683 | 0.93 | CYP2C9 (0.75) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL297529 | 0.91 | BRAF (0.83) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL21624556 | 0.91 | CYP2C19 (0.79) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL30866617 | 0.91 | CYP2C19 (0.79) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 | |
| SCHEMBL20408847 | 0.90 | BRAF (0.83) | CYP2C9CYP2C19CYP2D6BRAFCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281864-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-09-08 | — | — | US | claimed |
| EP-3823968-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HepaRegeniX GmbH (DE) | 2021-05-26 | — | — | EP | claimed |
| WO-2020016243-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2020-01-23 | — | — | WO | claimed |
| CN-112424201-B | Protein kinase inhibitors that promote liver regeneration or reduce or prevent hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20220281864-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2022-09-08 | — | — | US | disclosed |
| CN-112424201-A | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | CYP2C9 1742/4885CYP2C19 2763/4885CYP2D6 1384/4885 |
| US-20220281864-A1 | PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAPK7, MAPK14 | CYP2C9 1814/4885CYP2C19 2855/4885CYP2D6 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.